Gennaro Daniele

4.1k total citations · 1 hit paper
100 papers, 1.9k citations indexed

About

Gennaro Daniele is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gennaro Daniele has authored 100 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Gennaro Daniele's work include Lung Cancer Treatments and Mutations (31 papers), HER2/EGFR in Cancer Research (16 papers) and Colorectal Cancer Treatments and Studies (16 papers). Gennaro Daniele is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), HER2/EGFR in Cancer Research (16 papers) and Colorectal Cancer Treatments and Studies (16 papers). Gennaro Daniele collaborates with scholars based in Italy, United States and France. Gennaro Daniele's co-authors include Francesco Perrone, Fortunato Ciardiello, Maria Carmela Piccirillo, Giampaolo Tortora, Roberto Bianco, Massimo Di Maïo, Alessandro Morabito, Gaetano Rocco, Giovanni Scambia and Jane Bryce and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Gennaro Daniele

90 papers receiving 1.9k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

2015 330 citations Massimo Di Maïo, Ciro Gallo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gennaro Daniele Italy	24	970	577	559	262	179	100	1.9k
Maria Carmela Piccirillo Italy	26	1.2k 1.3×	787 1.4×	502 0.9×	408 1.6×	223 1.2×	94	2.3k
Sunil Sharma United States	22	643 0.7×	409 0.7×	538 1.0×	134 0.5×	214 1.2×	71	1.6k
Jeffrey P. Hodge United States	20	1.3k 1.3×	566 1.0×	794 1.4×	246 0.9×	73 0.4×	39	2.3k
Stephen Welch Canada	24	1.0k 1.1×	388 0.7×	626 1.1×	279 1.1×	176 1.0×	124	1.9k
Erika Cecchin Italy	27	1.5k 1.5×	406 0.7×	1.2k 2.1×	363 1.4×	218 1.2×	125	2.6k
Lola A. Fashoyin‐Aje United States	20	1.1k 1.1×	450 0.8×	295 0.5×	349 1.3×	221 1.2×	69	1.9k
Christine Brezden‐Masley Canada	24	1.1k 1.1×	405 0.7×	311 0.6×	440 1.7×	249 1.4×	106	2.1k
Francesco Pignatti Netherlands	28	854 0.9×	612 1.1×	479 0.9×	265 1.0×	174 1.0×	102	2.8k
Lucìa Mangone Italy	22	1.3k 1.3×	484 0.8×	345 0.6×	373 1.4×	289 1.6×	96	2.1k

Countries citing papers authored by Gennaro Daniele

Since Specialization

Citations

This map shows the geographic impact of Gennaro Daniele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gennaro Daniele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gennaro Daniele more than expected).

Fields of papers citing papers by Gennaro Daniele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gennaro Daniele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gennaro Daniele. The network helps show where Gennaro Daniele may publish in the future.

Co-authorship network of co-authors of Gennaro Daniele

This figure shows the co-authorship network connecting the top 25 collaborators of Gennaro Daniele. A scholar is included among the top collaborators of Gennaro Daniele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gennaro Daniele. Gennaro Daniele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iannantuono, Giovanni Maria, Charalampos S. Floudas, Marco Filetti, et al.. (2025). Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023). European Journal of Cancer. 225. 115589–115589.

Vita, Emanuele, Armando Orlandi, Gennaro Daniele, et al.. (2024). The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis. Cancer Treatment and Research Communications. 41. 100842–100842. 3 indexed citations

Dziadziuszko, Rafał, Fabrice Barlési, Jeong Eun Kim, et al.. (2024). Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.. Journal of Clinical Oncology. 42(17_suppl). LBA2509–LBA2509.

Filetti, Marco, Mario Occhipinti, Alessio Cirillo, et al.. (2024). Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature. Cancers. 16(23). 3955–3955. 1 indexed citations

Iavarone, Federica, Elisa De Paolis, Gennaro Daniele, et al.. (2024). Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges. International Journal of Molecular Sciences. 25(16). 8830–8830. 5 indexed citations

Giusti, Raffaele, Marco Filetti, Pasquale Lombardi, et al.. (2023). Out-of-pocket costs burden for cancer treatment toxicities and symptoms management in Italy: A prospective, multicenter pilot study.. Journal of Clinical Oncology. 41(16_suppl). 12105–12105. 1 indexed citations

Falcone, Rosa, Marco Filetti, Pasquale Lombardi, et al.. (2023). Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers. SHILAP Revista de lepidopterología. 4(4). 716–726. 1 indexed citations

Loong, Herbert H., Gennaro Daniele, Ticiana Leal, et al.. (2023). 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088. Annals of Oncology. 34. S761–S762. 4 indexed citations

Giusti, Raffaele, Marco Filetti, Pasquale Lombardi, et al.. (2023). 2087P Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management. Annals of Oncology. 34. S1097–S1097. 1 indexed citations

10.

Falcone, Rosa, Pasquale Lombardi, Marco Filetti, et al.. (2022). Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years. Cancers. 14(4). 889–889. 18 indexed citations

11.

Nero, Camilla, Simona Duranti, Angelo Minucci, et al.. (2022). Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. Journal of Personalized Medicine. 12(10). 1746–1746. 6 indexed citations

12.

Iacovelli, Roberto, Chiara Ciccarese, Francesco Pierconti, et al.. (2022). Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers. Critical Reviews in Oncology/Hematology. 176. 103750–103750. 13 indexed citations

13.

Rossi, Antônio, Sara Pilotto, Luisa Carbognin, et al.. (2021). Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. SHILAP Revista de lepidopterología. 2(3). 207–222. 2 indexed citations

14.

Pietragalla, Antonella, Simona Duranti, Gennaro Daniele, et al.. (2021). Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Expert Opinion on Investigational Drugs. 30(2). 103–110. 8 indexed citations

15.

Duranti, Simona, Alessandra Fabi, Marco Filetti, et al.. (2021). Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. Cancers. 13(20). 5198–5198. 10 indexed citations

16.

Nero, Camilla, Francesca Ciccarone, Antonella Pietragalla, et al.. (2021). Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers. 13(6). 1298–1298. 30 indexed citations

17.

Duranti, Simona, Antonella Pietragalla, Gennaro Daniele, et al.. (2021). Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. Cancers. 13(9). 2089–2089. 29 indexed citations

18.

Califano, Daniela, Daniela Russo, Giosuè Scognamiglio, et al.. (2020). Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells. 9(4). 903–903. 2 indexed citations

19.

Maïo, Massimo Di, Ciro Gallo, Natasha B. Leighl, et al.. (2015). Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology. 33(8). 910–915. 330 indexed citations breakdown →

20.

Bianco, Roberto, Roberta Rosa, Vincenzo Damiano, et al.. (2008). Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research. 14(16). 5069–5080. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact